AUROBINDO

August 2, 2022

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub : Completion of US FDA Inspection at our Unit XI – Reg.,
Ref : Our Letters dated May 17, 2019 and June 21, 2019

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and further to our above referred letters, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected the Company's Unit XI, an API non-antibiotic manufacturing facility situated at Pydibhimavaram, Srikakulam District, Andhra Pradesh, from July 25 to August 2, 2022.

The said Unit has been classified as OAI on May 17, 2019 and subsequently given a warning letter dated June 20, 2019. The Company has responded to the warning letter and carried out the committed corrections. The US FDA authorities have inspected the facility from July 25 to August 2, 2022.

At the end of the inspection, we have been issued a 'Form 483' with 3 observations and none of these observations are related to data integrity. We will respond to the US FDA within the stipulated timeline and work closely with USFDA to address the observations at the earliest.

We will keep the stock exchanges further informed if there are any material information relating to the above in the future.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary